22694-45-7

Upstream product

• 110-86-1 pyridine 
• 6334-18-5 2,3-dichlorobenzylaldehyde 
• 696-61-7 4-tolylmagnesium chloride 
• 3282-30-2 pivaloyl chloride 

Downstream Products

• 184536-49-0 (CO)5WCH(C₅H₅N)((CH₂)4OC₆H₅) 
• 184536-41-2 (CO)5WCH((CH₂)2C₆H₅)(C₅H₅N) 
• 14586-49-3 (pyridine)pentacarbonyltungsten⁽⁰⁾ 
• 199982-70-2 (CO)5WCH((CH₂)3CCC₆H₅)NC₅H₅ 
• 199982-69-9 (CO)5WCH((CH₂)3CCC₆H₅)NC₅H₅C(CH₃)2 
• 110-86-1 pyridine 
• 108-95-2 phenol 

Relevant academic research and scientific papers

Evaluation of Organic Hydride Donors as Reagents for the Reduction of Carbon Dioxide and Metal-Bound Formates

A variety of organic hydride donors (OHDs) have been tested as reagents for the transfer of hydride to iron formato complexes in the activation and reduction of carbon dioxide. Theoretical calculations show that the selection of OHD and solvent is crucial when planning systems involving OHD cooperativity. Strong consideration is given to the likelihood that metal centers may deactivate formate to hydride attack, since, in general, the formate group has more resonance stabilization energy when complexed to a metal center compared to an organoformate or formic acid. It is experimentally demonstrated that 1,2-dihydropyridine is not a competent reducing agent for carbon dioxide.

ARYLINDENOPYRIDINES AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS

This invention provides novel arylindenopyridines of the formula: and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing Adensine A2a receptors or reducing PDE activity in appropriate cells. This invention also provides therapeutic and prophylactic methods using the instant pharmaceutical compositions.

Arylindenopyridines and related therapeutic and prophylactic methods

This invention provides novel arylindenopyridines of the formula: and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing Adensine A2a receptors or reducing PDE activity in appropriate cells. This invention also provides therapeutic and prophylactic methods using the instant pharmaceutical compositions.

Arylindenopyridines and related therapeutic and prophylactic methods

This invention provides novel arylindenopyridines of the formula: , and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by reducing PDE activity in appropriate cells. This invention also provides therapeutic and prophylactic methods using the instant pharmaceutical compositions.

Benzosulfones and related compositions and methods

This invention provides novel benzosulfones of the following formulae: These compounds are useful as calcium channel antagonists with cardiovascular, antiasthmatic and antibronchoconstriction activity. Thus, this invention also provides pharmaceutical com

Process for preparing 4-(4'-carboxyphenyl)pyridine

The invention relates to a process for preparing 4-(4′-carboxyphenyl)pyridine, which comprises oxidizing a 4-phenyl-N-acyldihydropyridine of the formula (II) where R1 is a bulky alkyl, alkylaryl, arylalkyl or alkoxy group and R2 is a straight-chain or branched, substituted or unsubstituted alkyl radical having from 1 to 8 carbon atoms, by means of an oxidizing agent selected from the group consisting of permanganates, nitric acid, Cr(VI) compounds, oxygen and air to give the compound of the formula (I) where M is a cation.

DIHYDROPYRIDINE NPY ANTAGONISTS: PIPERAZINE DERIVATIVES

A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of piperazine and homopiperazine derivatives of 4-phenyl-1,4-dihydropyridines of Formula (I). STR1 As antagonists of NPY-induced feeding behavior, these compounds are e

DIHYDROPYRIDINE NPY ANTAGONISTS: NITROGEN HETEROCYCLIC DERIVATIVES

A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of nitrogen heterocyclic derivatives of 4-phenyl-1,4-dihydropyridines of Formula (I). STR1 As antagonists of NPY-induced feeding behavior, these compounds are expected

On the Structure and Mechanism of Formation of the Lansbury Reagent, Lithium Tetrakis(N-dihydropyridyl)aluminate

The reaction of lithium aluminium hydride (LAH) and pyridine yields five lithium tetrakis(N-dihydropyridyl)aluminate (LDPA) isomers.The LDPA isomers are formed reversibly and contain both 1,2- and 1,4-dihydropyridyl ligands.The 1,2-dihydropyridyl ligands are incorporated as the products of kinetic control while the 1,4-dihydropyridyl ligands are formed as the thermodynamic products.When LDPA is synthesized using lithium aluminium deuteride and the deuterated LDPA is placed in pyridine solvent, the ligands exchange with the pyridine in the solvent pool and form pyridine which is deuterated mainly in the 2- and 4-position.A small amount of 3-deuterated pyridine is also detected.The formation of 3-deuteriopyridine suggests that the pyridine radical anion is an intermediate present during the reaction of LAH with pyridine.In support of this suggestion, when LAH and pyridine are mixed, the EPR spectrum of the lithium salt of the pyridyl radical anion is observed.The stepwise addition of ligands to form LDPA is observed (NMR).Five aluminate species are detectable (27Al NMR): LAH , mono-, di-, and -trisubstituted aluminium hydride, and LDPA.The hydrolysis of LDPA in solvent pyridine-d5 yields a mixture of 1,4-, 1,2-, and 2,5-dihydropyridines.The dihydropyridines are stable in the absence of oxygen.

Heterocyclic compounds and their preparation and pharmaceutical formulation

Compounds are described of the formula: STR1 and physiologically acceptable salts thereof, in which R1 -R7 are defined hereinafter. The compounds represented by formula (I) reduce intracellular calcium ion concentration by limiting t